STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma
- 14 October 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (20), 4302-4311
- https://doi.org/10.1158/0008-5472.can-14-3331
Abstract
High grade gliomas (HGG) are classified into four subgroups based on transcriptional signatures and phenotypic characteristics. In particular, the proneural-to-mesenchymal transition (PMT) is associated with increased malignancy, poor prognosis, and disease recurrence, but the underlying causes of PMT are still unclear. In this study, we investigated whether radiotherapy promotes PMT using a genetically engineered mouse model of proneural HGG. We found that cranial ionizing radiation induced robust and durable PMT in tumors. Additionally, we isolated primary proneural HGG cells from mouse and human tumors and demonstrate that radiation induced a sustained cell-intrinsic mesenchymal transition associated with increased invasiveness and resistance to the alkylating agent temozolomide. Expectedly, irradiation-induced PMT was also associated with activation of the STAT3 transcription factor, and the combination of STAT3 blockade using JAK2 inhibitors with radiation abrogated the mesenchymal transition and extended survival of mice. Taken together, our data suggest that clinical JAK2 inhibitors should be tested in conjunction with radiation in patients with proneural HGG as a new strategy for blocking the emergence of therapy-resistant mesenchymal tumors at relapse. Cancer Res; 75(20); 4302–11. ©2015 AACR.Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 ComplexCancer Cell, 2012
- The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of GlioblastomaThe American Journal of Pathology, 2012
- Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical ApplicationPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2012
- The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant gliomaGenes & Development, 2011
- Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of OriginJournal of Clinical Oncology, 2011
- Non-Stem Cell Origin for OligodendrogliomaCancer Cell, 2010
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse GliomasPLOS ONE, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- The transcriptional network for mesenchymal transformation of brain tumoursNature, 2009